| Literature DB >> 34479479 |
Jing Duan1, Chuncheng Zhang2, Xiaoshuang Che3, Juanjuan Fu1, Feng Pang1, Qigang Zhao1, Zhiqing You4.
Abstract
BACKGROUND: Descending necrotizing mediastinitis (DNM) is one of the most virulent forms of mediastinitis. The main causes of high mortality in DNM are believed to stem from difficulty and delay in the diagnosis. Fast and accurate identification of pathogens is important for the treatment of these patients. Metagenomics next-generation sequencing (mNGS) is a powerful tool to identify all kinds of pathogens, especially for rare and complex infections. CASEEntities:
Keywords: Aerobe-anaerobe mixed infection; Descending necrotizing mediastinitis; mNGS
Mesh:
Year: 2021 PMID: 34479479 PMCID: PMC8417974 DOI: 10.1186/s12879-021-06624-4
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Physical examination and laboratory test during the period of hospitalization
| Indexes | Day 0 | Day 5 | Day 11 | Day 20 | |
|---|---|---|---|---|---|
| Physical examination | Axillary temperature: oxygen saturation: blood pressure: Status of affected area | 36.8 ℃ 99% 112/77 mmHg red and swollen | 37.3 ℃ 100% 135/72 mmHg red and swollen | 36.5 ℃ 100% 128/65 mmHg red and swollen | 36.7 ℃ 98% 114/68 mmHg swollen Improved |
| Laboratory test | WBC: (3.5–9.5) × 109 /L Neutrophil%: (40–75) % CRP: (0–10) mg/L PCT: (0–0.5) ng/L IL-6: ≤ 5.4 pg/ml IL-10: ≤ 12.9 pg/ml | 4.05 × 109/L 90.4% > 200 mg/L 9.32 ng/ml 387.06 pg/ml 69.19 pg/m | 5.77 × 109 /L 87% > 200 mg/L 9.77 ng/ml 330.04 pg/ml 50.82 pg/m | 4.61 × 109 /L 69.4 19.79 mg/L 1.06 ng/ml 153.56 pg/ml 34.42 pg/m | 7.53 × 109 /L 70.5 NA NA 60.22 pg/ml 26.72 pg/ml |
Fig. 1CT images of the patient at day 0, day 5 and day 11 of hospitalization.A–D The CT images of the patient at the time of admission, the mandibular space and mediastinum of the patient has obvious gas shadow, there is pleural effusion, and the lung image is normal; E–H The CT images of the patient 5 days after admission and treatment, the mandibular space and mediastinal gas after drainage treatment reduced, but the infection of the neck and mediastinum did not change significantly, the amount of pleural effusion increased compared with previous, and the lungs appeared as strips of increased density which indicating lung infection; I–L The CT images of the patient 11 days after admission, the submandibular space and mediastinal gas decreased, neck and mediastinal infections improved, lung infections improved, and pleural effusion decreased
Pathogens recovered by mNGS in drainage fluid
| Genus | Reads no. | Genus relative abundance | Species | Reads no. | Species relative abundance (%) |
|---|---|---|---|---|---|
| 202,442 | 48.59% | 78,656 | 18.32 | ||
| 27,149 | 8.53 | ||||
| 53,838 | 20.19% | 28,322 | 18.29 | ||
| 22,052 | 8.22% | 21,470 | 8.09 | ||
| 11,837 | 4.53% | 6789 | 3.67 | ||
| 11,472 | 3.63% | 11,347 | 3.58 |
Antimicrobial susceptibility testing results of cultured pathogens
| Pathogen | Antimicrobial agent | Method (unit) | Interpretive standard | |||||
|---|---|---|---|---|---|---|---|---|
| S | I | R | Result | Sensitivity | ||||
| Penicillin | MIC (ug/ml) | ≤ 0.12 | 0.25–2 | ≥ 4 | 0.064 | S | ||
| Linezolid | KB (mm) | ≥ 21 | NA | NA | 28 | S | ||
| Levofloxacin | KB (mm) | ≥ 17 | 14–16 | ≤ 13 | 28 | S | ||
| Ceftriaxone | KB (mm) | ≥ 27 | 25–26 | ≤ 24 | 30 | S | ||
| Vancomycin | KB (mm) | ≥ 17 | NA | NA | 22 | S | ||
| Erythromycin | KB (mm) | ≥ 21 | 16–20 | ≤ 15 | 6 | R | ||
| Azithromycin | KB (mm) | ≥ 18 | 14–17 | ≤ 13 | 6 | R | ||
| Clindamycin | KB (mm) | ≥ 19 | 16–18 | ≤ 15 | 6 | R | ||
| Clarithromycin | KB (mm) | ≥ 21 | 17–20 | ≤ 16 | 6 | R | ||
| Tetracycline | KB (mm) | ≥ 23 | 19–22 | ≤ 18 | 30 | S | ||
| Penicillin | MIC (ug/ml) | ≤ 0.12 | NA | ≥ 0.25 | ≥ 0.50 | R | ||
| Vancomycin | MIC (ug/ml) | ≤ 4 | 8–16 | ≥ 32 | 1.0 | S | ||
| Gentamicin | MIC (ug/ml) | ≤ 4 | 8 | ≥ 16 | 1.0 | S | ||
| Clindamycin | MIC (ug/ml) | ≤ 0.5 | 1–2 | ≥ 4 | ≥ 8.0 | R | ||
| Tetracycline | MIC (ug/ml) | ≤ 4 | 8 | ≥ 16 | ≥ 16.0 | R | ||
| Ciprofloxacin | MIC (ug/ml) | ≤ 1 | 2 | ≥ 4 | 1.0 | S | ||
| Levofloxacin | MIC (ug/ml) | ≤ 1 | 2 | ≥ 4 | 0.5 | S | ||
| Moxifloxacin | MIC (ug/ml) | ≤ 0.5 | 1 | ≥ 2 | ≤ 0.25 | S | ||
| Smz-tmp | MIC (ug/ml) | ≤ 2/38 | NA | ≥ 4/76 | 80.0 | R | ||
| Rifampicin | MIC (ug/ml) | ≤ 1 | 2 | ≥ 4 | ≤ 0.5 | S | ||
| Quinupristin/dalfopristin | MIC (ug/ml) | ≤ 1 | 2 | ≥ 4 | 0.5 | S | ||
| Linezolid | MIC (ug/ml) | ≤ 4 | NA | ≥ 8 | 2.0 | S | ||
| Erythromycin | MIC (ug/ml) | ≤ 0.5 | 1–4 | ≥ 8 | ≥ 8.0 | R | ||
| Oxacillin | MIC (ug/ml) | ≤ 0.25 | NA | ≥ 0.5 | ≥ 4.0 | R | ||
| Methicillin resistance | Positive | |||||||
| Piperacillin/tazobactam | MIC (ug/ml) | ≤ 16/4 | 32/4–64/4 | ≥ 128/4 | 16.0 | S | ||
| Ceftazidime | MIC (ug/ml) | ≤ 8 | 16 | ≥ 32 | 32.0 | R | ||
| Imipenenm | MIC (ug/ml) | ≤ 2 | 4 | ≥ 8 | ≥ 16.0 | R | ||
| Meropenem | MIC (ug/ml) | ≤ 2 | 4 | ≥ 8 | ≤ 0.25 | S | ||
| Amikacin | MIC (ug/ml) | ≤ 16 | 32 | ≥ 64 | ≥ 64.0 | R | ||
| Ciprofloxacin | MIC (ug/ml) | ≤ 0.5 | 1 | ≥ 2 | 0.5 | S | ||
| Levofloxacin | MIC (ug/ml) | ≤ 1 | 2 | ≥ 4 | 1.0 | S | ||
| Cefoperazone/sulbactam | MIC (ug/ml) | ≤ 16 | 32 | ≥ 64 | 32.0 | I | ||
| Cefepime | MIC (ug/ml) | ≤ 8 | 16 | ≥ 32 | 16.0 | I | ||
| Tobramycin | MIC (ug/ml) | ≤ 4 | 8 | ≥ 16 | 2.0 | S | ||
| Polymyxin | MIC (ug/ml) | ≤ 2 | NA | ≥ 4 | 2.0 | S | ||
| Gentamicin | KB (mm) | ≥ 15 | 13–14 | ≤ 12 | 17 | S | ||
Fig. 2Schedule of lab test, diagnosis and therapy. --:normal, ↑ : above normal; ↑↑:beyond up limit; ↓ below normal